Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa

In a large trial conducted in four African nations, hydroxyurea was safely administered to children with sickle cell disease and led to significant increases in hemoglobin and fetal hemoglobin levels and significant reductions in the incidence of pain crises, infection, malaria, transfusion, and dea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-01, Vol.380 (2), p.121-131
Hauptverfasser:	Tshilolo, Léon, Tomlinson, George, Williams, Thomas N, Santos, Brígida, Olupot-Olupot, Peter, Lane, Adam, Aygun, Banu, Stuber, Susan E, Latham, Teresa S, McGann, Patrick T, Ware, Russell E
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Body weight Children Clinical trials Data collection Design Drug dosages Enrollments FDA approval Fetuses Hemoglobin Hospitals Hydroxyurea Laboratories Malaria Malnutrition Medical screening Neutrophils Pain Patients Safety Sickle cell anemia Sickle cell disease
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a large trial conducted in four African nations, hydroxyurea was safely administered to children with sickle cell disease and led to significant increases in hemoglobin and fetal hemoglobin levels and significant reductions in the incidence of pain crises, infection, malaria, transfusion, and death.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1813598